eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Clinical research

Comparison of the efficacy and safety of hybrid and sequential therapies as a first-line regimen for Helicobacter pylori infection in Turkey

Ayşe Kefeli, Sebahat Başyigit, Abdullah Ozgur Yeniova, Serdar Ozkan, Yasar Nazligul

Arch Med Sci 2018; 14, 2: 276–280
Online publish date: 2016/03/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: Helicobacter pylori infection is a common infection worldwide. The most frequently recommended treatment for eradication of H. pylori remains triple therapy. In this study, we compared sequential and hybrid regimens for H. pylori eradication in a region of Turkey with high resistance to clarithromycin.

Material and methods: Three hundred and forty H. pylori-positive patients were enrolled in the study. The subjects were randomly divided into two groups. The first group (170 patients) received rabeprazole (40 mg/b.i.d.) and amoxicillin (1000 mg/b.i.d.) for 2 weeks and metronidazole and clarithromycin (500 mg/b.i.d.) during the second week in the hybrid therapy group. The second group (170 patients) received rabeprazole (40 mg/b.i.d.) for 14 days, amoxicillin (1000 mg/b.i.d.) for the first 7 days, and metronidazole plus clarithromycin (each 500 mg/b.i.d.) during the next 7 days in the sequential therapy group.

Results: In the per-protocol analysis, the eradication rate in the hybrid therapy group was 96.1% (147/153), and in the sequential therapy group it was 90.9% (140/154). There was no significant difference between the two groups (p = 0.06). Ninety-seven of those 340 patients reported minor adverse drug reactions. The percentages of patients with adverse reactions were 30.6% in the hybrid therapy group and 26.5% in the sequential therapy group (p = 0.74).

Conclusions: Both therapies are highly effective for eradication of H. pylori, and could be recommended as a first-line therapy in regions with high antibiotic resistance.
keywords:

Helicobacter pylori, hybrid regimen, sequential regimen

references:
McColl KE. Clinical practice Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-604.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Consensus Report. Gut 2012; 61: 646-64.
Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-600.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed Aliment Pharmacol Ther 2011; 34: 1255-68.
Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-45.
De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63: 748-52.
Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129-34.
Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylorii eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647-50.
Molina-Infante J, Romano M, Federico A, et al. 14-day, high-dose acid suppression, non-bismuth quadruple therapies (hybrid vs. concomitant) for Helicobacter pylori infection: a randomized trial. Gastroenterology 2013; 144: 242 (Abstract: Presented in Digestive Disease Week (DDW) 18-21 May, 2013 Orlando, FL).
Wu JY, Hsu PI, Wu DC, Graham D. Optimal duration to maintain greater than 95% eradication rate in hybrid therapy for H. pylorii. Gastroenterology 2012; 142: 484 (Abstract: Presented in Digestive Disease Week (DDW) 19-21 May, 2012, San Diego).
Graham DY, Gisbert JP. Helicobacter pylori: tailored therapy with novel sequential quadruple therapies. Nat Rev Gastroenterol Hepatol 2013; 10: 6-8.
Oh DH, Lee DH, Kang KK, et al. Efficacy of hybrid and sequential therapies as first line treatment for H. pylorii infection in Korea. J Gastroenterol Hepatol 2013; 28: 327 (Abstract: Presented in Asian Pacific Digestive Week (DDW) 2013 |World Congress of Gastroenterology, 21-24 September 2013, Shanghai Expo Center, Shanghai, China).
Hsu P, Wu D, Wu J, Graham D. Search for a Grade A therapy for H. pylorii eradication: 14-day sequential or sequential concomitant hybrid therapy. Helicobacter 2010; 15: 314 (Abstract; Presented in XXIII International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Infl ammation and Gastric Cancer , 16-18 September, 2010, Rotterdam).
Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-8.
He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54: 703-10.
Wang B, Wang YH, Lv ZF, et al. Efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79-88.
Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86.
Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin- containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-70.
Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76.
Sezgin O, Aslan G, Altintaş E, Tezcan S, Serin MS, Emekdaş G. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. Turk J Gastroenterol 2008; 19: 163-7.
Cağdaş U, Otağ F, Tezcan S, Sezgin O, Aslan G, Emekdaş G. Detection of Helicobacter pylori and antimicrobial resistance in gastric biopsy specimens. Bul Mic 2012; 46: 398-409.
Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19: 67-70.
Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-8.
Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11.
De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100.
Yakut M, Çinar K, Seven G, Bahar K, Özden A. Sequential therapy for Helicobacter pylori eradication. Turk J Gastroenterol 2010; 21: 206-11.
Demir M, Ataseven H. The effects of sequential treatment as a first-line therapy for Helicobacter pylori eradication. Turk J Med Sci 2011; 41: 427-33.
Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther 2008; 30: 528-34.
Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol 2010; 105: 1071-5.
Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357-62.
Losurdo G, Leandro G, Principi M, et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by ‘geographical weighting’. Int J Clin Pract 2015; 69: 1112-20.
Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009; 54: 269-78.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe